US OptionsDetailed Quotes

ALVR240719C5000

Watchlist

0.05
0.000.00%

15min DelayClose Apr 30 10:47 ET

0.00High0.00Low

AlloVir Stock Discussion

Moomoo AI

Dec 28, 2023 07:04

AlloVir's reassuring cash runway contrasts with worrying cash burn in relation to its market cap, raising concerns of funding stress and heightening stock uncertainty.

We're Keeping An Eye On AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Trytosaveabit

Dec 22, 2023 06:22

Resume trade at 7:30AM est TIMBER???

$AlloVir(ALVR.US)$ Hehehe! SUX! But could offer a bottom buy then see if a big Pharmaceutical company offers to buy the rest of their research?

Trytosaveabit

Dec 22, 2023 06:11

This could get ugly when halt comes off

$AlloVir(ALVR.US)$ AlloVir Says It Will Discontinue Its Three Phase 3 Posoleucel Studies Following Separate, Pre-planned DSMB Futility Analyses Concluding Studies Were Unlikely To Meet Primary Endpoints
Moomoo 24/7· 1 min ago

GAME_DAY

Jun 22, 2023 08:29

TOP AM WATCH ⚡️⚡️

ROOT AAOI RNAZ PIXY BOF TALS PBLA ALVR IVDA LCFY
$Root Inc(ROOT.US)$ $Applied Optoelectronics(AAOI.US)$ $Transcode Therapeutics(RNAZ.US)$ $ShiftPixy(PIXY.US)$ $BranchOut Food(BOF.US)$ $Talaris Therapeutics(TALS.US)$ $Panbela Therapeutics(PBLA.US)$ $AlloVir(ALVR.US)$ $Iveda Solutions(IVDA.US)$ $Locafy(LCFY.US)$

GAME_DAY

Jun 21, 2023 16:45

TOP WATCH AH + 6/22 ⚡️⚡️

$Applied Optoelectronics(AAOI.US)$ $Ault Disruptive Technologies Corporation(ADRT.US)$ $AlloVir(ALVR.US)$ $BranchOut Food(BOF.US)$ $Chemomab Therapeutics(CMMB.US)$ $Cognizant(CTSH.US)$ $Greenpro Capital(GRNQ.US)$ $IDEX Corp(IEX.US)$ $Eightco Holdings(OCTO.US)$ $ShiftPixy(PIXY.US)$ $Root Inc(ROOT.US)$ $PTC Therapeutics(PTCT.US)$ $Summit Therapeutics(SMMT.US)$ $ZoomInfo(ZI.US)$

Analysts Notebook

Aug 24, 2022 07:22

ColumnsUS Top Rating Updates on 8/24: TWTR, PLD, MDT, XPEV and More

Twitter Downgraded at Rosenblatt as Whistleblower Complaint 'Heightens Risks'
Investment firm Rosenblatt downgraded $Twitter (Delisted)(TWTR.US)$ on Wednesday as the debate surrounding the whistleblower complaint from its former head of security has raised the risks surrounding the stock. Analyst Barton Crockett lowered his rating to neutral from buy and lowered his price target to $37 from $52, noting there are now "meaningful uncertainties" surr...